Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2026
2025
2024
2023
2022
2021
2020
2019

2022.05.26

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

2022.05.12

Adagene to Participate in Investor Conferences in May and June

2022.04.08

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022

2022.03.31

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update

2022.03.16

Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab

Pagination

First page
Previous page
…
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
…
Next page
Last page

Displaying 66 - 70 of 112

Shareholder Tools

© 2026 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn